Oncology, answered.

Flatiron Health at ASH 2026

December 12–15

New Orleans, LA

Booth 723

13 research acceptances

Request a meeting

Amy Pierre, MSN, RN, ANP-BC, Senior Clinical Director at Flatiron Health

Real-world evidence for your highest-stakes hematology decisions

Answer your most complex questions with real-world data on nearly 600K patients with hematologic malignancies, paired with deep clinical expertise and AI-powered insights.

Experience Flatiron’s hematology Panoramic data

Visit our booth to experience our hematology data live in Flatiron Telescope, our AI-powered intelligence platform.

Book a live demo

Flatiron networking reception at The Barnett

Saturday, December 12, 2026

7:30–9:30 PM CT

Just us for an evening of networking, cocktails and hors d'oeuvres at our exclusive networking reception. RSVP is required.

RSVP now

Get an exclusive first look at Flatiron’s research at ASH

Flatiron’s Senior Clinical Director sat down to discuss how Flatiron’s real-world evidence reveals the why behind hematology treatment decisions

Learn more

Preview our research at ASH 2026

Thirteen poster presentations feature Flatiron data, including seven Flatiron-led studies. Our accepted research demonstrates the breadth of questions real-world evidence can answer in hematology—from identifying hidden high-risk patients in multiple myeloma to understanding what comes next after CAR T and why clinicians choose the therapies they do—generating insights in collaboration with partners across the oncology ecosystem

Let’s turn evidence into smarter, faster decisions

Poster presentations

Treatment patterns across lines of therapy among patients with newly diagnosed multiple myeloma in the United States

Author affiliations: H. Lee Moffitt Cancer Center and Research Institute, Karmanos Cancer Institute, Michigan State University, Hackensack Meridian School of Medicine, John Theurer Cancer Center, Emory Winship Cancer Institute, GSK, Flatiron Health, Providence Cancer Center Oncology and Hematology Care Clinic

Session Title: 653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Date and Time: December 12, 2026, 5:30-7:30 PM

Real-world treatment patterns of novel immune-based therapy utilization in relapsed/refractory multiple myeloma: evidence from a contemporary cross-sectional analysis

Author affiliations: Hackensack Meridian Health, Providence Cancer Center Oncology and Hematology Care Clinic, Moffitt Cancer Center, Emory Winship Cancer Institute, Flatiron Health, GSK, Karmanos Cancer Institute, Michigan State University

Session Title: 907. Outcomes Research: Plasma Cell Disorders: Poster III

Date and Time: December 14, 2026, 6:00-8:00 PM

Real-World Safety and Effectiveness of Elranatamab in Multiple Myeloma, including in late-line and BCMA-exposed patients

Author affiliations: UC Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Center, Pfizer, Flatiron Health

Session Title: 907. Outcomes Research: Plasma Cell Disorders: Poster I

Date and Time: December 12, 2026, 5:30-7:30 PM

Unmasking hidden risk: clinical and real-world factors associated with functional high-risk multiple myeloma and their impact on treatment and outcomes — a real-world evidence study

Author affiliations: Flatiron Health

Session Title: 907. Outcomes Research: Plasma Cell Disorders: Poster II

Date and Time: December 13, 2026, 6:00-8:00 PM

When MRD matters: clinical interpretation and treatment decision-making after measurable residual disease testing in multiple myeloma

Author affiliations: Flatiron Health

Session Title: 907. Outcomes Research: Plasma Cell Disorders: Poster II

Date and Time: December 13, 2026, 6:00-8:00 PM

Real-world comparison of biologic features, treatment patterns, and clinical outcomes between younger (≤55 years) and older (>55 years) patients with CLL receiving frontline targeted therapy

Author affiliations: Huntsman Cancer Institute, Flatiron Health

Session Title: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

Date and Time: December 12, 2026, 5:30-7:30 PM

Beyond treatment patterns: clinician-documented decision-making following dual BTK inhibitors and BCL2 inhibitor exposure in chronic lymphocytic leukemia

Author affiliations: Flatiron Health

Session Title: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II

Date and Time: December 13, 2026, 6:00-8:00 PM

Qualitative assessment of physician-documented drivers for switching covalent BTK inhibitors in CLL/SLL in real-world practice

Author affiliations: Rutgers Cancer Institute, BeOne Medicines, Flatiron Health, Yale School of Medicine

Session Title: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II

Date and Time: December 13, 2026, 6:00-8:00 PM

Frontline treatment and consolidation strategies and associated outcomes in primary central nervous system lymphoma: a large US real-world study

Author affiliations: Flatiron Health

Session Title: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III

Date and Time: December 14, 2026, 6:00-8:00 PM

Real-world treatment patterns and outcomes over time of patients with high-grade B-cell lymphoma in a large US oncology network

Author affiliations: Flatiron Health

Session Title: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II

Date and Time: December 13, 2026, 6:00-8:00 PM

Association of lymphopenia with outcomes in diffuse large B cell lymphoma in the era of T- cell directed therapies

Author affiliations: University Hospitals of Leicester, Flatiron Health, University of Leicester

Session Title: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders

Date and Time: December 12, 2026, 5:30-7:30 PM

The CAR-T funnel: AI-assisted mapping of patient attrition and barriers across the second-line CAR-T pathway in relapsed/refractory diffuse large B-cell lymphoma

Author affiliations: Levine Cancer Institute Atrium Health, Flatiron Health

Session Title: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I

Date and Time: December 12, 2026, 5:30-7:30 PM

Treatment patterns and outcomes post-CAR T failure in LBCL: the "what comes next" question

Author affiliations: Flatiron Health

Session Title: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I

Date and Time: December 12, 2026, 5:30-7:30 PM